Introduction
============

Colorectal cancer (CRC) is the third most frequent cancer and the fourth most common cause of cancer-associated mortality globally, with an annual incidence of 17.2/100,000 people and an age-standardized mortality rate of 8.4/100,000 people worldwide ([@b1-ol-0-0-5078],[@b2-ol-0-0-5078]). The preferred treatment option is complete surgical resection, yet in up to 30% of cases the cancer recurs either locally or as distant metastasis ([@b2-ol-0-0-5078]). In order to reduce the incidence of disease recurrences, chemotherapy or radiochemotherapy are indicated, in addition to surgery in certain patients. It has been shown that only patients with cancer that has spread to the local lymph nodes benefit from these additional treatment options ([@b1-ol-0-0-5078]). Therefore, appropriate pre- and post-operative tumor-node-metastasis (TNM) staging is crucial for the optimal treatment of CRC patients and for the estimation of their prognosis ([@b1-ol-0-0-5078],[@b3-ol-0-0-5078]). Follow-up for several years after treatment is necessary for the early detection of disease recurrence ([@b2-ol-0-0-5078]).

Since surgery is the treatment of choice in CRC, the completeness of the surgical removal of the tumor is the most important treatment-related prognostic factor in CRC patients. The completeness of the surgical removal of the tumor is expressed in terms of the R category: R0 meaning the complete removal of the tumor, R1 meaning microscopic residual disease and R2 meaning macroscopic residual disease ([@b4-ol-0-0-5078],[@b5-ol-0-0-5078]).

The two most important prognostic factors (the stage of the disease at diagnosis and residual disease after surgical resection) are assessed by the pathohistological analysis of the resected tumor specimen. Clinical decisions regarding adjuvant treatment or follow-up after surgery are based on the pathohistological analysis of the removed specimen and are based on the probability of malignant tissue remaining in the patient ([@b6-ol-0-0-5078]). A more direct and effective method would be to introduce a biomarker that could measure the disease burden, as well as the residual disease, directly in the patient\'s body ([@b7-ol-0-0-5078]).

This idea has led to the search for a specific molecular marker in the peripheral blood for the detection of minimal residual disease after the primary treatment of CRC. The majority of investigated molecular markers have been tumor-associated membrane proteins, such as cytokeratin 20 (CK20), and tumor-specific DNA mutations, such as KRAS proto-oncogene, GTPase (*KRAS*) ([@b8-ol-0-0-5078]). The detection of minimal residual disease in the peripheral blood through the use of molecular markers has been shown to have an impact on a patient\'s prognosis in a number of studies, although the methods are not yet sufficiently standardized for clinical use ([@b9-ol-0-0-5078]--[@b11-ol-0-0-5078]).

The present study was aimed at determining the expression of CK20 and the presence of *KRAS* and B-Raf proto-oncogene, serine/threonine kinase (*BRAF*) tumor-specific mutations in DNA isolated from the peripheral blood prior to and following surgery, in order to assess whether the serological markers can be used to determine the stage of the disease at diagnosis and the R status after surgery.

Materials and methods
=====================

### Patients

The study was approved by the Republic of Slovenia National Medical Ethics Committee (Ljubljana, Slovenia). All patients made an informed decision to take part in the study and provided written consent. Patients were informed that the results of tests would not be disclosed to them, as they would not affect the standard treatment provided, to which all patients consented.

A total of 65 patients scheduled for elective surgery at University Medical Centre Ljubljana (Ljubljana, Slovenia) due to CRC or adenomas between July 2011 and January 2012 were enrolled into the study. The patients were staged into Union for International Cancer Control (UICC) TNM categories and stages according to the pre-operative staging results, intraoperative findings and pathohistological results of the resected specimens, as described previously ([@b1-ol-0-0-5078]). After surgery, the pathohistological analysis of the resected specimens was performed in a standard manner ([@b3-ol-0-0-5078]). The clearance of tumor tissue by surgery was expressed by R category based on surgery reports and pathohistological analysis of the resected specimen.

### Samples

Formalin-fixed paraffin-embedded (FFPE) tumor tissue and matched normal tissue samples were obtained from each patient. The appropriate FFPE tumor and normal tissue block was selected by the pathologist, who also evaluated the percentage of tumor cells in the paraffin slides from the first and last hematoxylin and eosin (HE)-stained sections. Six consecutive non-colored FFPE sample cuts between the HE colored sections with the thickness of 10-µm were prepared in an Eppendorf tube by the pathologist. Additionally, from each patient, the peripheral whole blood samples were collected immediately prior to the surgery and 5--7 days after the surgery. The whole blood samples were collected in 10-ml EDTA tubes and stored at −80°C. The samples (1 ml) were centrifuged at 1,700 × *g* for 25 min at 4°C to obtain pellets (cells and cellular debris). These pellets were then used for DNA and RNA extraction.

### DNA isolation

For the DNA extraction, a QIAamp DNA FFPE kit (Qiagen, Hilden, Germany) was used according to the manufacturer\'s protocols. The DNA from the blood samples was extracted using an Arrow Blood DNA kit (NorDiag, Dublin, Ireland) according to the manufacturer\'s protocols. After the isolation, the DNA concentration was measured spectrophotometrically at 280/260 nm using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA).

### RNA isolation

Total RNA was isolated from the blood using an miRNeasy Mini kit (Qiagen) according to the manufacturer\'s protocols. RNA was quantified using the NanoDrop spectrophotometer, and cDNA was synthesized from 500 ng of the total RNA using the High-Capacity cDNA Reverse Transcription kit with RNase Inhibitor (Applied Biosystems; Thermo Fisher Scientific, Inc. Foster City, CA, USA), according to the manufacturer\'s protocols.

### Determination of KRAS and BRAF mutations

Determination of *KRAS* and *BRAF* mutation status was performed using the KRAS/BRAF Mutation Analysis kit (EntroGen, Tarzana, CA, USA) for a quantitative polymerase chain reaction (qPCR) assay based on allele-specific PCR. The assay is designed to preferentially amplify mutant DNA even in samples that have mostly wild-type DNA. In the assay, an endogenous control gene is included in order to ensure that a sufficient amount of DNA is available for amplification. The detection of the amplification product is performed using fluorescent hydrolysis probes. The assay was performed according to the manufacturer\'s protocols, with 25 ng DNA per reaction using an ABI7900 system (Applied Biosystems; Thermo Fisher Scientific, Inc.). For data analysis, the manufacturer\'s instructions were followed (EntroGen). The KRAS/BRAF Mutation Analysis kit includes primers and probes for detection of the 18 most common *KRAS* mutations in codons 12, 13, 61, 117 and 146, and a single *BRAF* mutation in codon 600 ([Table I](#tI-ol-0-0-5078){ref-type="table"}).

### Determination of CK20 gene expression

Reverse transcription-qPCR (RT-qPCR) was performed using a LightCycler 480 instrument (Roche Applied Science, Mannheim, Germany). The primers used for amplification of the target gene, CK20, and a housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), were as follows: CK20 forward, 5′-CTGAATAAGGTCTTTGATGACC-3′ and reverse, 5′-ATGCTTGTGTAGGCCATCGA-3′; and GAPDH forward, 5′-GAAGGTGAAGGTCGGAGTC-3′ and reverse, 5′-GAAGATGGTGATGGGATTTC-3′, as described previously by Shen *et al* ([@b12-ol-0-0-5078]). RT-qPCR was set up in triplicate in 384-well plates and performed in 10-µl reactions with 2X LightCycler 480 SYBR Green I Master (Roche Applied Science), 10 µM of each primer (Applied Biosystems) and 300 ng cDNA. The thermocycling conditions were as follows: 95°C for 10 min, and 45 cycles of 95°C for 15 sec, 60°C for 45 sec and 72°C for 15 sec, followed by a melting curve construction by increasing the temperature from 65--95°C with a temperature transition rate of 0.1°C/sec. A melting curve analysis was performed to verify that the product consisted of a single amplicon. In each experiment, the control group consisted of a pool of RNA samples isolated from the whole blood of healthy volunteers. The data were analyzed by Roche LightCycler 480 software (Roche Applied Science) using the advanced relative quantification method, according to the manufacturer instructions, where the ΔCq values of a control group were used for normalization.

### Statistical analysis

Statistical analyses were performed using IBM SPSS Statistics Version 20 (IBM SPSS, Armonk, NY, USA). As the dependent variable could be assumed to be normally distributed, a Jocheere-Terpstra test was used for testing the difference in the relative CK20 levels between TNM stages. Fisher\'s exact test was used for comparing the presence of specific tumor mutations in the peripheral blood, vascular invasion and lymphatic infiltration between TNM stages. A Mann-Whitney test was used for testing the difference between the levels of CK20 in groups described as R0 and R2 resections. Fisher\'s exact test was used for testing the difference in the change patterns of tumor mutations between the groups described as R0 and R2 resections. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Detection of tumor-specific DNA mutations

In 35/65 patients, the primary tumor tested positive for the specific mutations (*KRAS* mutations in codons 12, 13, 61, 117 and 146, and *BRAF* mutations in codon 600) ([Table II](#tII-ol-0-0-5078){ref-type="table"}). In all these patients, the specimen of normal bowel resected with the tumor was also tested for the presence of the same mutations in order to exclude the germ-line mutations. Only patients who tested positive for the specific mutation in the primary tumor were included in further analysis ([Fig. 1](#f1-ol-0-0-5078){ref-type="fig"}).

The mean age of the 35 mutation-positive patients was 68 years (range, 43--83 years), and 21 (60%) of the patients were male and 14 (40%) were female.

The stage distribution of these 35 patients was 4, 14, 8 and 5 patients in UICC stages I, II, III and IV, respectively. In 4 patients, the resected specimen turned out to be a non-malignant adenoma. A total of 14 tumors were located in the right colon or hepatic flexure, 3 tumors were located in the splenic flexure or left colon, 11 tumors were located in the sigmoid colon or in the region of rectosigmoid junction, and 7 tumors were located in the rectum. Only one of the rectal tumors was treated pre-operatively with 5×5 Gy short-course radiotherapy.

Regarding the radicality of surgery, there were 30 R0 resections and 5 R2 resections. The R2 resections were all due to non-resectable liver metastases. Overall, 8 (23%) of the resections were performed laparoscopically and 27 (77%) were performed using the classic surgical technique.

The same mutation as in the primary tumor was detected in the first blood sample of 11 patients (31%). In the second blood sample, the same mutation as in the tumor was detected in 6 patients (17%). Additionally, 2 of the patients who were negative for the mutation in the first blood sample were positive for the mutation in the second blood sample ([Table II](#tII-ol-0-0-5078){ref-type="table"}).

### Tumor stage at the time of surgery

The median relative levels of CK20 were 1.91, 1.95, 2.05 and 2.17 for tumor stages I, II, III and IV, respectively. The differences in relative CK20 levels in the peripheral blood between the different UICC stages were not statistically significant (P=0.689).

The same specific mutation as in the primary tumors was found in the peripheral blood of 2 out of 4 (50%) patients in stage I, in 3 out of 14 patients (21%) in stage II, in 2 out of 8 patients (25%) in stage III and in 3 out of 5 patients (60%) in stage IV ([Fig. 2](#f2-ol-0-0-5078){ref-type="fig"}). Vascular invasion was reported in 1, 3, 2 and 3 tumor specimens of stages I, II, III and IV, respectively. Lymphocyte infiltration was reported in 3, 7, 3 and 3 tumor specimens of stages I, II, III and IV, respectively. The differences between UICC stages were not statistically significant regarding the proportion of tumor-specific mutations found in the peripheral blood, vascular invasion or lymphocyte infiltration (P=0.491, P=0.435, and P=0.717, respectively) ([Table III](#tIII-ol-0-0-5078){ref-type="table"}).

In the group of patients with adenomas, the specific mutation was found in the peripheral blood of 1 out of 4 patients (25%); the median level of CK20 was 1.68 (range, 1.28--1.84) ([Fig. 2](#f2-ol-0-0-5078){ref-type="fig"}). Information on vascular invasion or lymphocyte infiltration was not provided in the pathohistological report.

### Residual disease after surgery

In the group of patients with R0 resections, the specific mutations were found in the peripheral blood of 8/30 patients (27%) prior to surgery and in 3/30 patients (10%) after surgery. The median levels of CK20 were 1.82 (range, 0.97--3.73) prior to surgery and 2.34 (range, 1.11--11.29) after surgery. In the R2 resection group, the specific mutations in the peripheral blood were detected in 3/5 of the patients (60%) prior to and after surgery. The median levels of CK20 were 2.16 (range, 2.02--3.14) and 2.60 (range, 2.42--2.87) prior to and after surgery, respectively.

The proportion of patients with the various patterns of tumor-specific mutations in the blood samples prior to and after the surgery was significantly different between the groups of patients described as R0 and R2 resections (P=0.038, [Fig. 3](#f3-ol-0-0-5078){ref-type="fig"}). There was a higher proportion of patients with detected specific tumor mutations in each blood sample (collected prior to and after the surgery) in the R2 resection group.

The change in CK20 level was not statistically significantly different between the groups of patients described as R0 and R2 resection (P=0.671).

Discussion
==========

According to the current understanding of tumor biology, the dissemination of the primary tumor is a complex process that occurs rather early in the course of the disease. It is known that numerous tumor cells are shed daily from the tumor even at early stages of the disease and that the majority of these cells die off very quickly in the peripheral circulation ([@b13-ol-0-0-5078],[@b14-ol-0-0-5078]). Therefore, it was first thought that the detection of circulating tumor cells (CTCs) in the peripheral blood would be the ultimate tool for monitoring the activity of the disease. However, the detection of CTCs turned out to be more complicated than expected. CTCs are extremely rare cells hidden in the background of numerous normal blood cells ([@b15-ol-0-0-5078]). From studies with proven metastatic CRC, it is known that only a few CTCs, if any at all, are found in standard blood probes ([@b16-ol-0-0-5078]). For the detection of CTCs, different molecular markers have been used, yet only some of them are specific for CTCs ([@b17-ol-0-0-5078],[@b18-ol-0-0-5078]). It was previously shown that specific DNA mutations found in tumors can mostly be found in metastases and also in isolated CTCs ([@b19-ol-0-0-5078],[@b20-ol-0-0-5078]). Therefore, it has been proposed that circulating free tumor DNA in the peripheral blood may be a good estimate of CTCs and of disease burden ([@b21-ol-0-0-5078]--[@b23-ol-0-0-5078]). It is expected that there should be no tumor DNA present in the circulation after the surgical removal of the whole tumor ([@b24-ol-0-0-5078]). The presence of tumor-specific DNA in the peripheral blood following primary tumor removal would be an indication of active metastatic sites in the patient\'s body, i.e., residual disease after surgery.

A few studies performed on CRC patients support the concept of serological staging by reporting a statistically significant association between CK20 levels or tumor-specific DNA mutations in the DNA from the peripheral blood and the tumor stage ([@b12-ol-0-0-5078],[@b25-ol-0-0-5078]--[@b27-ol-0-0-5078]). Therefore, the aim of the present study was to assess whether the detection of the expression of CK20 and the presence of *KRAS* and *BRAF* tumor-specific mutations in the peripheral blood can be used to determine the stage of a CRC patient prior to surgery and the R status after surgery.

However, no statistically significant correlation could be found between the relative levels of CK20 or the presence of tumor-specific *KRAS* or *BRAF* mutations in DNA from the peripheral blood prior to surgery and the UICC disease stage. These results are in concordance with the results of numerous other studies that also failed to confirm the correlation between CK20, the presence of *KRAS* mutated or other tumor-derived DNA in the blood of CRC patients and the tumor stage ([@b28-ol-0-0-5078]--[@b35-ol-0-0-5078]). The present study was also not able to confirm a statistically significant correlation between residual disease after surgery, as described by R category, and CK20 levels in the blood prior to and following surgery.

However, statistically significant differences were found with regard to the proportions of patients with detected tumor-specific DNA mutations in the peripheral blood between the groups of patients with R0 and R2 resections. Statistical significance was associated with all patterns (combinations) of mutation presence in the blood samples prior to and following surgery. Tumor-specific DNA mutations in the peripheral blood were more frequently detected in the patients with incomplete surgical clearance of the tumor due to macroscopic residual disease (R2 resections). In the literature, only scant and indirect data exist on the correlation of the radicality of surgery and the levels of molecular markers in the blood in the post-operative period ([@b33-ol-0-0-5078]). Studies mainly report solely on the detection rate of different molecular markers in the blood after surgery and focus on the tumor recurrence during the follow-up period ([@b29-ol-0-0-5078],[@b32-ol-0-0-5078],[@b35-ol-0-0-5078]). A difference in pre- and post-operative levels of different molecular markers in the blood of patients operated upon for CRC has also been reported, yet with only an indirect correlation to the radicality of surgery ([@b36-ol-0-0-5078],[@b37-ol-0-0-5078]).

In the present study, tumor-specific DNA showed greater potential for residual disease detection than CK20. In theory, tumor-specific DNA also appears to be a more promising serological marker for tumor staging than non-specific epithelial markers, such as CK20. The main problem with using the detection of tumor-specific DNA in the peripheral blood for clinical use is the fact that there is no single tumor-specific mutation that can be found in all tumors of the same type ([@b38-ol-0-0-5078]). For CRC, for example, it is known that only up to 50% of all tumors have mutated *KRAS* ([@b39-ol-0-0-5078]). Even in proven mutated tumors the entire tumor cell population does not show specific mutations, but only certain portions of the tumor ([@b40-ol-0-0-5078],[@b41-ol-0-0-5078]). All of this has to be taken into account when interpreting the detection rates of specific tumor DNA mutations in the peripheral blood.

Despite conflicting evidence from previous studies, as well as the from results of the present study, the detection of tumor-specific DNA in the peripheral blood remains a promising, but highly challenging method for estimating the tumor burden at diagnosis and the residual disease after resection ([@b42-ol-0-0-5078]). The possibility of serological staging by the detection of tumor-specific DNA from the peripheral blood would be of great clinical importance in situations in which no tumor tissue is available for standard pathohistological staging. The important clinical issues of the residual disease after surgery, regression of the tumor after neoadjuvant or adjuvant treatment and the follow-up on watch-and-wait strategy of CRC patients with complete response after radiochemotherapy are all not assessable by pathohistological analysis ([@b43-ol-0-0-5078]). This fact is also recognized by the most recent, 7th edition, of the TNM classification, which moved away from the purely pathological to the clinicopathological staging in order to improve a number of the clinically apparent shortcomings of previous editions ([@b44-ol-0-0-5078]). With evolving diagnostic tools and treatment modalities, the concept of staging will inevitably drift away from the pathohistological analysis of the specimens even more in the future.

Overall, the present study concludes that the follow-up of somatic *KRAS*- and *BRAF*-mutated DNA in the peripheral blood of CRC patients may be useful in assessing the surgical clearance of the disease. Regardless of all the difficulties associated with the improvement of blood-specific DNA-based staging and the follow-up of CRC, the concept of serological staging may gain importance in the near future. Until then, good clinical and pathohistological staging and R category determination should remain the gold standard upon which all novel techniques are to be measured.

![Schedule of *KRAS*/*BRAF* mutation testing. For each patient, the *KRAS*/*BRAF* mutation status was first determined in the tumor tissue sample. When a mutation was detected, the normal tissue sample was tested to exclude the samples with the germ-line mutation. When the normal tissue was negative (wild-type), the blood samples were tested for the presence of the *KRAS*/*BRAF* mutation determined in the matched tumor tissue sample. *KRAS*, KRAS proto-oncogene, GTPase; *BRAF*, B-Raf proto-oncogene, serine/threonine kinase.](ol-12-05-3356-g00){#f1-ol-0-0-5078}
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![Percentage of patients with tumor-specific mutations in the peripheral blood prior to and following surgery in groups described as R0 and R2 resections.](ol-12-05-3356-g02){#f3-ol-0-0-5078}

###### 

List of *KRAS* and *BRAF* mutations covered by the KRAS/BRAF mutation analysis kit (EntroGen).

  Gene     Exon   Nt change    aa change
  -------- ------ ------------ ---------------
  *KRAS*   2      c.34G\>C     p.Gly12Arg
                  c.34G\>T     p.Gly12Cys
                  c.34G\>A     p.Gly12Ser
                  c.35G\>T     p.Gly12Val
                  c.35G\>C     p.Gly12Ala
                  c.35G\>A     p.Gly12Asp
                  c.38G\>A     p.Gly13Asp
           3      c.182A\>G    p.Gln61Arg
                  c.183A\>C    p.Gln61His
                  c.183A\>T    p.Gln61His
                  c.182A\>T    p.Gln61Leu
           4      c.351A\>C      p.Lys117Asn
                  c.351A\>T      p.Lys117Asn
                  c.350A\>G      p.Lys117Arg
                  c.349A\>G      p.Lys117Glu
                  c.436G\>A      p.Ala146Thr
                  c.436G\>C      p.Ala146Pro
                  c.437C\>T      p.Ala146Val
  *BRAF*   15     c.1799T\>A     p.Val600Glu

Nt, nucleotide; aa, amino acid; *KRAS*, KRAS proto-oncogene, GTPase; *BRAF*, B-Raf proto-oncogene, serine/threonine kinase.

###### 

Type and distribution of *KRAS*/*BRAF* mutations in colorectal cancer patients.

  Sample   Tumor tissue   Normal tissue   Blood sample collected prior to surgery   Blood sample collected 5--7 days after surgery
  -------- -------------- --------------- ----------------------------------------- ------------------------------------------------
    1      p.Gln61Arg     wt              wt                                        wt
    2      p.Gly12Asp     wt              wt                                        wt
    3      p.Gly12Asp     wt              wt                                        wt
    4      p.Gly12Arg     wt              wt                                        wt
    5      p.Gly12Ser     wt              wt                                        wt
    6      p.Gly12Asp     wt              wt                                        wt
    7      p.Gly12Asp     wt              wt                                        wt
    8      p.Gly12Asp     wt              p.Gly12Asp                                wt
    9      p.Gly12Val     wt              p.Gly12Val                                wt
  10       p.Gly12Val     wt              wt                                        wt
  11       p.Val600Glu    wt              wt                                        wt
  12       p.Val600Glu    wt              wt                                        wt
  13       p.Gly13Asp     wt              wt                                        wt
  14       p.Gln61His     wt              wt                                        p.Gln61His
  15       p.Gly12Asp     wt              p.Gly12Asp                                wt
  16       p.Gly12Val     wt              p.Gly12Val                                wt
  17       p.Gly12Asp     wt              wt                                        wt
  18       p.Gly12Asp     wt              wt                                        wt
  19       p.Gly12Asp     wt              wt                                        ND
  20       p.Gly12Cys     wt              p.Gly12Cys                                p.Gly12Cys
  21       p.Gly12Val     wt              p.Gly12Val                                wt
  22       p.Gly12Val     wt              p.Gly12Val                                wt
  23       p.Gly12Cys     wt              wt                                        wt
  24       p.Val600Glu    wt              wt                                        wt
  25       p.Gln61His     wt              wt                                        wt
  26       p.Gln61His     wt              wt                                        wt
  27       p.Gly12Ser     wt              wt                                        wt
  28       p.Ala146x      wt              p.Ala146x                                 p.Ala146x
  29       p.Val600Glu    wt              wt                                        wt
  30       p.Gln61Leu     wt              wt                                        p.Gln61Leu
  31       p.Gly12Asp     wt              p.Gly12Asp                                p.Gly12Asp
  32       p.Gln61His     wt              wt                                        wt
  33       p.Gly12Alaq    wt              wt                                        wt
  34       p.Gly12Asp     wt              p.Gly12Asp                                wt
  35       p.Ala146x      wt              p.Ala146x                                 p.Ala146x

wt, wild-type; ND, not determined; x, the type of amino acid is not determined (it is either p.Ala146Thr, p.Ala146Pro or p.Ala146Val). *KRAS*, KRAS proto-oncogene, GTPase; *BRAF*, B-Raf proto-oncogene, serine/threonine kinase.

###### 

Correlation of tumor-node-metastasis stages with vascular invasion and lymphocyte infiltration in primary tumors, as well as with the presence of specific DNA mutations and CK20 in peripheral blood.

                                   Stage of colorectal cancer                                                               
  -------------------------------- ---------------------------- ------------------- ------------------- ------------------- ----------------------------------------------------
  Vascular invasion, n (%)         1 (25)                       3 (21)              2 (25)              3 (60)              0.435^[a](#tfn3-ol-0-0-5078){ref-type="table-fn"}^
  Lymphocyte infiltration, n (%)   3 (75)                       7 (50)              3 (38)              3 (60)              0.717^[a](#tfn3-ol-0-0-5078){ref-type="table-fn"}^
  DNA mutation detected            2 (50)                       3 (21)              2 (25)              3 (60)              0.491^[a](#tfn3-ol-0-0-5078){ref-type="table-fn"}^
  Median (range) relative CK20     1.91 (1.57--3.14)            1.95 (0.97--3.32)   2.05 (1.09--3.73)   2.17 (2.02--3.14)   0.689^[b](#tfn4-ol-0-0-5078){ref-type="table-fn"}^

From Fisher\'s exact test.

From Joncheere-Terpstra test (exact P-value) assuming increasing order of relative CK20 level with increasing tumor stage. CK20, cytokeratin 20.
